Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201 Journal Article
| Authors: | Banerjee, S. N.; Van Nieuwenhuysen, E.; Aghajanian, C.; D'Hondt, V.; Monk, B. J.; Clamp, A.; Prendergast, E.; Oaknin, A.; Ring, K.; Colombo, N.; Holloway, R. W.; Rodrigues, M.; Chon, H. S.; Gourley, C.; Santin, A. D.; Thaker, P. H.; Gennigens, C.; Newman, G.; Salinas, E.; Youssoufian, H.; Moore, K. N.; Lustgarten, S.; O'Malley, D. M.; Van Gorp, T.; Grisham, R. N. |
| Article Title: | Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201 |
| Abstract: | PURPOSE: This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal adhesion kinase inhibitor) in patients with recurrent low-grade serous ovarian cancer (LGSOC). METHODS: In this phase II, open-label study, patients with recurrent, measurable LGSOC after ≥1 line of platinum chemotherapy were stratified by tumor Kirsten rat sarcoma virus homolog (KRAS) mutation status and randomly assigned to oral avutometinib 4.0 mg two times per week monotherapy or avutometinib 3.2 mg two times per week in combination with oral defactinib 200 mg two times per day. The combination was selected as the go-forward regimen for expansion. The primary end point was objective response rate (ORR) by blinded independent central review. RESULTS: A total of 115 patients received the go-forward combination regimen. Patients had a median of 3 (range, 1-9) prior lines of therapy, including hormonal (86%), bevacizumab (51%), and MEK inhibitor (22%). Confirmed ORR was 31% (95% CI, 23% to 41%) with a median duration of response of 31.1 months (95% CI, 14.8 to 31.1). ORR was 44% in KRAS-mutant and 17% in KRAS wild-type cohorts. The median progression-free survival was 12.9 months (95% CI, 10.9 to 20.2) overall and 22.0 months (95% CI, 11.1 to 36.6) and 12.8 months (95% CI, 7.4 to 18.4) in KRAS-mutant and wild-type cohorts, respectively. The most frequent grade ≥3 treatment-related adverse events (AEs) were elevated creatine phosphokinase (24%), diarrhea (8%), and anemia (5%). Ten percent of patients discontinued because of AEs. CONCLUSION: The efficacy and safety profile of avutometinib in combination with defactinib support this combination as a potential standard of care for recurrent LGSOC. A randomized phase 3 study of avutometinib and defactinib versus investigator's choice of therapy for women with recurrent LGSOC is currently enrolling (RAMP301; ClinicalTrials.gov identifier: NCT06072781). © 2025 American Society of Clinical Oncology. |
| Journal Title: | Journal of Clinical Oncology |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Publication status: | Online ahead of print |
| Date Published: | 2025-07-11 |
| Online Publication Date: | 2025-07-11 |
| Language: | English |
| DOI: | 10.1200/jco-25-00112 |
| PUBMED: | 40644648 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
175Grisham -
613Aghajanian
Related MSK Work